Science and Technology Innovation Leads Enterprise Development Zhifei Attends 2022 CIFTIS

The 2022 China International Fair for Trade in Services (CIFTIS) was held in Beijing from August 31st to September 5th. This is the largest comprehensive exhibition in the field of global trade in services. Themed Cooperate for Better Development, Innovate for a Greener Future, the 2022 CIFTIS adopts the mode of Comprehensive & Themed Exhibitions and Online & Offline to build a platform for exhibition, communication, negotiation and cooperation facing the world. Zhifei was invited to attend the 2022 CIFTIS.

Jiang Lingfeng, vice chairman and vice president of Zhifei, attended the Health and Industrial Technology Innovation Service Conference 2022 and delivered a keynote speech of Science and Technology Innovation Leads Enterprise Development. Jiang expressed that the biomedicine industry is the backbone of the treatment of major diseases and the prevention and control of infectious diseases, and its development is related to human life and health. Enterprises should combine the characteristics of industry innovation, seize the new opportunities of science and technology empowerment, strengthen the cooperation between industries, and realize the integrated development of science and technology.

Meanwhile, he introduced the innovative achievements of Zhifei, among which the Recombinant COVID-19 Vaccine (CHO Cell) is the first recombinant subunit COVID-19 vaccine approved for registration and marketing in the world and the first recombinant subunit COVID-19 vaccine approved for conditional marketing in China, with 81.4% protective efficacy against COVID-19 of any severity and 75.7% long-term protective efficacy at 6 months of vaccination. The Recombinant Mycobacterium Tuberculosis Fusion Protein (EC®) (C-TST) is a national Class 1 new drug for the diagnosis of Mycobacterium tuberculosis (M.tb) infection with high sensitivity and specificity. The diagnosis results are not affected by BCG vaccination, which has received special support from several national projects for major infectious diseases. Mycobacterium Vaccae for Injection (Vaccae®) has been approved for an additional indication for the prevention of TB in people with latent TB infection, becoming the only product successfully developed and marketed for the prevention of TB disease in people with latent TB infection since the advent of BCG vaccine one hundred years ago. He said that the product combination of EC® and Vaccae® will provide the Zhifei solution to TB prevention and control at home and abroad.

Academician Zeng Yixin, member of the leading organization of the Party and Vice Director of the National Health Commission, Mr. Wang Jiangping, member of the Leading organization and Vice Minister of the Ministry of Industry and Information Technology visited the booth of Zhifei. Ms. Xie Li, Vice president of Zhifei, reported to the leaders. She mentioned that the second-generation Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell) developed by Zhifei, has completed all the pharmaceutical and toxicological studies to support clinical trials, including industrial production process validation, safety and efficacy validation. Against the current mainstream Omicron BA.4/5 variants, the vaccine has a higher neutralizing antibody titer.

In recent years, Zhifei has been expanding the layout of emerging technologies, consolidating the independent R & D capacity, covering a wide range of vaccine development paths, and building nine major vaccine R & D technology platforms. Meanwhile, the company attaches significance to the introduction of technology and accelerates the cooperation of technology. The innovation strategy of Primary In-house R & D, Complementary Cooperative R & D, Supplementary Investment & Incubation has boosted the enterprise to achieve high-quality development.

In the future, Zhifei will continue adhering to the concept of innovative development, increasing R&D investment, expanding R&D technology platform, enriching R&D pipeline, building and improving R&D innovation capability with continuous move, fulfilling the enterprise responsibility of biomedicine with practical actions, realizing the effective transformation from science and technology innovation to social benefits, contributing to the construction of the defense line of human life and health.